Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: A retrospective case series.

被引：0
|
作者：
Chamberlain, Marc C.
Kim, Bryan T.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.e13538
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e13538
引用
收藏
页数：5
相关论文
共 50 条
  • [11] Retrospective study of carmustine or lomustine with bevacizumab in recurrent glioblastoma patients who have failed prior bevacizumab
    Rahman, Rifaquat
    Hempfling, Kelly
    Norden, Andrew D.
    Reardon, David A.
    Nayak, Lakshmi
    Rinne, Mikael L.
    Beroukhim, Rameen
    Doherty, Lisa
    Ruland, Sandra
    Rai, Arun
    Rifenburg, Jennifer
    LaFrankie, Debra
    Alexander, Brian M.
    Huang, Raymond Y.
    Wen, Patrick Y.
    Lee, Eudocia Q.
    NEURO-ONCOLOGY, 2014, 16 (11) : 1523 - 1529
  • [12] Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series
    Ansstas, George
    Tran, David D.
    CASE REPORTS IN NEUROLOGY, 2016, 8 (01): : 1 - 9
  • [13] COMPARATIVE OUTCOMES OF BEVACIZUMAB AND PCV CHEMOTHERAPY IN PATIENTS WITH RECURRENT AND PROGRESSIVE GLIOBLASTOMA: A RETROSPECTIVE STUDY
    Dixit, Sanjay
    Mohan, Annette
    Aziz
    Achawal, Shailendra
    O'Rielley, Gerry
    Rajaraman, Chitoor
    Baker, Louise
    Gill, Lynn
    Hingorani, Mohan
    NEURO-ONCOLOGY, 2014, 16
  • [14] BEVACIZUMAB AND IRINOTECAN IN THE TREATMENT OF PATIENTS WITH RECURRENT GLIOBLASTOMA
    Naskhletashvili, D. R.
    Gorbounova, V.
    Bychkov, M.
    Bekyashev, A.
    Karakhan, V.
    Aloshin, V.
    Fu, R.
    Moskvina, E.
    NEURO-ONCOLOGY, 2012, 14 : 59 - 59
  • [15] Bevacizumab residual concentration for recurrent glioblastoma patients
    Tabouret, E.
    Rousseau, B.
    Barrie, M.
    Thiebault, L.
    Chinot, O.
    Hulin, A.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2016, 30 : 26 - 26
  • [16] Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    C. Lu-Emerson
    A. D. Norden
    J. Drappatz
    E. C. Quant
    R. Beroukhim
    A. S. Ciampa
    L. M. Doherty
    D. C. LaFrankie
    S. Ruland
    P. Y. Wen
    Journal of Neuro-Oncology, 2011, 104 : 287 - 291
  • [17] Retrospective study of dasatinib for recurrent glioblastoma after bevacizumab failure
    Lu-Emerson, C.
    Norden, A. D.
    Drappatz, J.
    Quant, E. C.
    Beroukhim, R.
    Ciampa, A. S.
    Doherty, L. M.
    LaFrankie, D. C.
    Ruland, S.
    Wen, P. Y.
    JOURNAL OF NEURO-ONCOLOGY, 2011, 104 (01) : 287 - 291
  • [18] Pazopanib and taxane combinations for metastatic or recurrent soft tissue sarcoma: A retrospective case series.
    Sarkissian, Sarmen
    Fruehauf, John P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [19] Degradation fragments of Tau and type IV collagen as serum biomarkers in patients with recurrent glioblastoma treated with nivolumab and bevacizumab
    Jensen, Christina
    Maarup, Simone
    Poulsen, Hans Skovgaard
    Hasselbalch, Benedikte
    Karsdal, Morten
    Svane, Inge Marie
    Lassen, Ulrik
    Willumsen, Nicholas
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2024,
  • [20] Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
    Reardon, David A.
    Brandes, Alba A.
    Omuro, Antonio
    Mulholland, Paul
    Lim, Michael
    Wick, Antje
    Baehring, Joachim
    Ahluwalia, Manmeet S.
    Roth, Patrick
    Baehr, Oliver
    Phuphanich, Surasak
    Sepulveda, Juan Manuel
    De Souza, Paul
    Sahebjam, Solmaz
    Carleton, Michael
    Tatsuoka, Kay
    Taitt, Corina
    Zwirtes, Ricardo
    Sampson, John
    Weller, Michael
    JAMA ONCOLOGY, 2020, 6 (07) : 1003 - 1010
12345